XML 32 R22.htm IDEA: XBRL DOCUMENT v3.5.0.2
Note 1 - Organization and Nature of Business (Details Textual)
2 Months Ended 3 Months Ended
Apr. 15, 2016
USD ($)
$ / shares
shares
Mar. 02, 2016
USD ($)
shares
Feb. 13, 2016
Feb. 12, 2016
USD ($)
$ / shares
shares
Apr. 15, 2016
USD ($)
$ / shares
shares
Mar. 31, 2016
USD ($)
$ / shares
shares
Mar. 31, 2015
USD ($)
Dec. 31, 2015
$ / shares
shares
Protagenic Therapeutics Inc [Member] | Series B Preferred Stock [Member] | New Options [Member]                
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross       1,807,744        
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $ / shares       $ 0.87        
Protagenic Therapeutics Inc [Member] | Series B Preferred Stock [Member] | Predecessor Options [Member]                
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross       17,784        
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $ / shares       $ 1.25        
Class of Warrant or Right, Number of Securities Called by Warrants or Rights       295,945        
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares       $ 1.25        
Protagenic Therapeutics Inc [Member] | Series B Preferred Stock [Member] | New Warrants [Member]                
Class of Warrant or Right, Number of Securities Called by Warrants or Rights       3,403,367        
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares       $ 1.03        
Protagenic Therapeutics Inc [Member] | Series B Preferred Stock [Member]                
Common Shares Exchanged for Preferred Shares       (6,612,838)        
Preferred Stock, Par or Stated Value Per Share | $ / shares       $ 0.000001        
Protagenic Therapeutics Inc [Member] | Placement Agent Warrants [Member]                
Class of Warrant or Right, Number of Securities Called by Warrants or Rights       127,346        
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares       $ 1.25        
Protagenic Therapeutics Inc [Member] | Predecessor Warrants [Member]                
Class of Warrant or Right, Number of Securities Called by Warrants or Rights       295,945        
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares       $ 1.25        
Protagenic Therapeutics Inc [Member] | Private Placement [Member]                
Class of Warrant or Right, Number of Securities Called by Warrants or Rights       3,403,367        
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares       $ 1.05        
Protagenic Therapeutics Inc [Member]                
Business Acquisition, Conversion of Stock, Ratio       1        
Business Combination, Stock Warrant Conversion Ratio       1        
Stock Issued During Period, Shares, Conversion of Series A Preferred Stock to Series B Preferred Stock       297,468        
Stock Issued During Period, Shares, Converted Shares Which Would Become Shares of Common Stock Upon Effectiveness of Reverse Split       297,468        
Series B Preferred Stock [Member] | Placement Agent Warrants [Member] | Private Placement [Member] | Subsequent Event [Member]                
Class of Warrant or Right, Number of Securities Called by Warrants or Rights 127,346       127,346      
Class of Warrant or Right, Value of Securities Called by Warrants or Rights | $ $ 146,641       $ 146,641      
Series B Preferred Stock [Member] | Predecessor Warrants [Member]                
Class of Warrant or Right, Number of Securities Called by Warrants or Rights       295,945        
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares       $ 1.25        
Warrants Issued for Settlement and Conversion of Debt | $       $ 340,784        
Series B Preferred Stock [Member] | Including Conversion of Principal and Interest [Member] | Private Placement [Member] | Subsequent Event [Member]                
Proceeds from Issuance of Private Placement | $         5,135,575      
Proceeds From Issuance of Private Placement, Net of Issuance Costs | $         $ 4,783,438      
Series B Preferred Stock [Member] | Private Placement [Member] | Subsequent Event [Member]                
Stock Issued During Period, Shares, New Issues 420,260       4,108,460      
Proceeds from Issuance of Convertible Preferred Stock | $ $ 525,325              
Proceeds from Issuance of Private Placement | $         $ 4,635,575      
Proceeds From Issuance of Private Placement, Net of Issuance Costs | $         $ 4,283,438      
Series B Preferred Stock [Member] | Private Placement [Member]                
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares       $ 1.25        
Shares Issued, Price Per Share | $ / shares       $ 1.25        
Stock Issued During Period, Value, New Issues | $       $ 3,468,750        
Stock Issued During Period, Shares, New Issues   913,200            
Proceeds from Issuance of Convertible Preferred Stock | $   $ 1,141,500            
Series B Preferred Stock [Member] | Reverse Stock Split [Member]                
Stockholders' Equity Note, Stock Split, Conversion Ratio       15,463.7183        
Series B Preferred Stock [Member]                
Preferred Stock, Par or Stated Value Per Share | $ / shares           $ 0.000001   $ 0.000001
Proceeds from Issuance of Convertible Preferred Stock | $           $ 3,778,250  
Preferred Stock, Shares Outstanding       9,685,306   0   0
Preferred Stock, Shares Authorized           18,000,000   18,000,000
Placement Agent Warrants [Member] | Private Placement [Member] | Subsequent Event [Member]                
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares $ 1.25       $ 1.25      
Predecessor [Member]                
Common Stock, Shares, Outstanding       400,000,000        
Common Stock, Par or Stated Value Per Share | $ / shares       $ 0.000001        
Common Stock [Member]                
Stock Issued During Period, Shares, Reverse Stock Split, Post-split       25,867        
Stock Issued During Period, Value, New Issues | $              
Stock Issued During Period, Shares, New Issues              
Debt Principal Conversion to Predecessor Warrants [Member]                
Debt Conversion, Original Debt, Amount | $       $ 665,000        
Debt Interest Conversion to Predecessor Warrants [Member]                
Debt Conversion, Original Debt, Amount | $       35,000        
Conversion of Outstanding Stockholder Debt [Member] | Predecessor's Stockholder [Member]                
Stock Issued During Period, Value, Conversion of Convertible Securities | $       150,000        
Conversion of Outstanding Stockholder Debt [Member] | Chairman and Board Member Garo H. Armen [Member]                
Stock Issued During Period, Value, Conversion of Convertible Securities | $       $ 350,000        
Momspot LLC [Member]                
Noncontrolling Interest, Ownership Percentage by Parent       51.00%        
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners       49.00%        
Interest Ownership Split Off     51.00%          
Investors in the Private Offering [Member]                
Number of Common Stock Held As Converted Basis       2,775,000        
Private Placement [Member] | Subsequent Event [Member] | Expense Allowance [Member]                
Payment of Financing and Stock Issuance Costs | $ $ 15,000              
Private Placement [Member] | Subsequent Event [Member]                
Payments of Stock Issuance Costs | $ 159,183              
Payments of Additional Legal and Miscellaneous Fees | $ 266,727              
Proceeds from Issuance of Private Placement | $ $ 525,325              
Stock Conversion from Series B Preferred Stock to Common Stock [Member]                
Convertible Preferred Stock, Shares Issued upon Conversion       1        
Convertible Preferred Stock, Aggregate Shares Issued Upon Conversion       9,685,306        
Preferred Stock, Par or Stated Value Per Share | $ / shares       $ 0.000001        
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross           100,000    
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $ / shares           $ 1.25    
Common Stock, Shares, Outstanding           400,000,000   6,613,338
Common Stock, Par or Stated Value Per Share | $ / shares       $ 0.0001   $ 0.000001   $ 0.001
Number of Wholly-Owned Subsidiaries Split Off     29          
Stock Issued During Period, Value, New Issues | $           $ 4,256,610    
Warrants Issued for Settlement and Conversion of Debt | $           $ 340,784  
Stock Shares Authorized       120,000,000        
Common Stock, Shares Authorized       100,000,000   100,000,000,000   20,000,000
Preferred Stock, Shares Authorized       20,000,000